Morgan Cheatham

Morgan Cheatham is a Vice President at Bessemer Venture Partners, a prominent global venture capital firm with over $9 billion in assets under management. He specializes in investments within the healthcare and life sciences sectors, focusing on companies that leverage unique datasets and computational methods to enhance patient care across various stages of development, from pre-seed to growth.123

Cheatham's background includes a Bachelor of Science in Neuroeconomics from Brown University, where he graduated magna cum laude. He is currently pursuing his medical degree at The Warren Alpert Medical School of Brown University, integrating his medical training with his investment expertise to identify emerging trends and opportunities in healthcare.123

Before joining Bessemer, he worked as an investment banking analyst at Goldman Sachs and as a data scientist at Kyruus, a healthcare IT startup. His investment portfolio includes notable companies such as Hinge Health, Folx Health (where he serves on the board), and Ginger, among others. Cheatham has been recognized for his contributions to the field, receiving accolades such as the Forbes 30 Under 30 award in Venture Capital and the National Venture Capital Association Rising Star Award in 2023.134

In addition to his investment role, Cheatham is involved in research and thought leadership within the healthcare space, contributing to publications and serving on the editorial team of NEJM AI. His work emphasizes the intersection of artificial intelligence and healthcare, aiming to drive innovations that improve patient outcomes and healthcare delivery systems.234